305 related articles for article (PubMed ID: 35525913)
1. A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma.
Kobayashi S; Fukushima T; Ueno M; Moriya S; Chuma M; Numata K; Tsuruya K; Hirose S; Kagawa T; Hattori N; Watanabe T; Matsunaga K; Suzuki M; Uojima H; Hidaka H; Kusano C; Suzuki M; Morimoto M
BMC Cancer; 2022 May; 22(1):517. PubMed ID: 35525913
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of transarterial chemoembolization (TACE) combined with lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular carcinoma.
Liu J; Yan S; Zhang G; Yang L; Wei S; Yi P
Oncol Lett; 2023 Dec; 26(6):507. PubMed ID: 37920437
[TBL] [Abstract][Full Text] [Related]
4. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
[TBL] [Abstract][Full Text] [Related]
6. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study.
Cai M; Huang W; Liang W; Guo Y; Liang L; Lin L; Xie L; Zhou J; Chen Y; Cao B; Wu J; Zhu K
Liver Int; 2024 Apr; 44(4):920-930. PubMed ID: 38291865
[TBL] [Abstract][Full Text] [Related]
8. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.
Llovet JM; Vogel A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo M
Cardiovasc Intervent Radiol; 2022 Apr; 45(4):405-412. PubMed ID: 35119481
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
10. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
Kudo M; Ueshima K; Saeki I; Ishikawa T; Inaba Y; Morimoto N; Aikata H; Tanabe N; Wada Y; Kondo Y; Tsuda M; Nakao K; Ito T; Hosaka T; Kawamura Y; Kuzuya T; Nojiri S; Ogawa C; Koga H; Hino K; Ikeda M; Moriguchi M; Hisai T; Yoshimura K; Furuse J; Arai Y
Liver Cancer; 2024 Feb; 13(1):99-112. PubMed ID: 38344448
[TBL] [Abstract][Full Text] [Related]
11. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).
Peng Z; Fan W; Zhu B; Wang G; Sun J; Xiao C; Huang F; Tang R; Cheng Y; Huang Z; Liang Y; Fan H; Qiao L; Li F; Zhuang W; Peng B; Wang J; Li J; Kuang M
J Clin Oncol; 2023 Jan; 41(1):117-127. PubMed ID: 35921605
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
[TBL] [Abstract][Full Text] [Related]
14. Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma.
Zhang M; Lai W; Zhang J; Hu B; Huang L; Chu C
Dis Markers; 2022; 2022():6957580. PubMed ID: 35845129
[TBL] [Abstract][Full Text] [Related]
15. Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):583-588. PubMed ID: 29040991
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
17. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage.
Cappelli A; Sangro P; Mosconi C; Deppe I; Terzi E; Bilbao JI; Rodriguez-Fraile M; De Benedittis C; Ricke J; Golfieri R; Sangro B
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):661-668. PubMed ID: 30209522
[TBL] [Abstract][Full Text] [Related]
18. Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.
Hirooka M; Hiraoka A; Ochi H; Kisaka Y; Joko K; Michitaka K; Hiasa Y
AJR Am J Roentgenol; 2018 Apr; 210(4):891-898. PubMed ID: 29412017
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
Acad Radiol; 2024 May; ():. PubMed ID: 38760273
[TBL] [Abstract][Full Text] [Related]
20. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]